Effectiveness of infliximab biosimilars in the treatment of moderate to severe chronic plaque psoriasis: experience of real-world data from the register of the program “Treatment of moderate and severe forms of plaque psoriasis (B.47)” of the National Health Fund in Poland

INTRODUCTION: Infliximab (IFX) is a monoclonal antibody that binds to and neutralizes TNF-α. IFX (Remicade) was approved by the U.S. Food and Drug Administration in 2006 for the treatment of severe plaque psoriasis. In 2013 two infliximab biosimilars: Remsima and Inflectra were also registered. The...

Descripción completa

Detalles Bibliográficos
Autores principales: Owczarek, Witold, Walecka, Irena, Nowakowska, Agnieszka, Ciechanowicz, Piotr, Reich, Adam, Lesiak, Aleksandra, Borkowska, Ewa, Śliwczyñski, Andrzej, Narbutt, Joanna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2021
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9454371/
https://www.ncbi.nlm.nih.gov/pubmed/36090728
http://dx.doi.org/10.5114/ada.2021.108442

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9454371/
https://www.ncbi.nlm.nih.gov/pubmed/36090728
http://dx.doi.org/10.5114/ada.2021.108442

Ejemplares similares